TABLE 3.
Summary of subgroup analysis on cerebral infarct volume.
| Pooled estimates | No. of studies | Std. MD (95% CI) | p value | Group p-value |
|---|---|---|---|---|
| Model | 0.10 | |||
| MCAO | 26 | −4.99 [−6.08, −3.90] | p < 0.00001 | |
| BCCAO | 3 | −3.78 [−4.74, −2.83] | p < 0.00001 | |
| Species | 0.23 | |||
| SD rats | 24 | −4.83 [−5.92, −3.73] | p < 0.00001 | |
| Long-Evans rats | 1 | −17.93 [−35.33, −0.54] | p = 0.04 | |
| Wistar rats | 4 | −4.02 [−5.63, −2.40] | p = 0.03 | |
| Route of administration | <0.00001 | |||
| i.p | 20 | −5.18 [−6.46, −3.91] | p < 0.00001 | |
| i.v | 7 | −5.06 [−6.72, −3.40] | p = 0.003 | |
| i.g | 1 | −1.04 [−2.02, −0.06] | p = 0.04 | |
| ICA | 1 | −2.54 [−4.44, −0.65] | p = 0.008 | |
| Dosage | 0.04 | |||
| <20 mg/kg | 12 | −3.07 [−4.32, −1.83] | p < 0.00001 | |
| 20 mg/kg | 8 | −3.51 [−5.00, −2.01] | p < 0.00001 | |
| 30 mg/kg | 8 | −5.83 [−7.63, −4.04] | p < 0.00001 | |
| >30 mg/kg | 8 | −5.46 [−7.58, −3.34] | p < 0.00001 | |
| Administration time | 0.58 | |||
| Before I/R | 18 | −5.05 [−6.41, −3.70] | p < 0.00001 | |
| After I/R | 10 | −4.50 [−6.15, −2.85] | p < 0.00001 | |
| Before and after I/R | 2 | −3.14 [−6.62, −0.34] | p = 0.0008 | |
| Occlusion time | 0.04 | |||
| 60 min | 3 | −10.89 [−16.35, −5.42] | p < 0.0001 | |
| 90 min | 6 | −5.12 [−7.57, −2.67] | p < 0.0001 | |
| 120 min | 18 | −4.02 [−5.08, −2.97] | p < 0.00001 | |
BCCAO, the bilateral common carotid arteries occlusion; MCAO, middle cerebral artery occlusion; ICA, intra-carotid artery; I/R, ischemia/reperfusion; i.g., intragastric gavage; i.p., intraperitoneal; i.v., intravenous injection; SD, Sprague-Dawley.